Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.[Image: see text]

Detalles Bibliográficos
Autores principales: Miyauchi, Masaaki, Toyoda, Masao, Zhang, Jie, Hamada, Naoko, Yamawaki, Takashi, Tanaka, Jun, Harada, Kazuki, Kashizaki, Fumihiro, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232357/
https://www.ncbi.nlm.nih.gov/pubmed/31587459
http://dx.doi.org/10.1111/jdi.13143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232357/
https://www.ncbi.nlm.nih.gov/pubmed/31587459
http://dx.doi.org/10.1111/jdi.13143

Ejemplares similares